Premium
Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study
Author(s) -
Onderdijk A.J.,
Ijpma A.S.,
Menting S.P.,
Baerveldt E.M.,
Prens E.P.
Publication year - 2015
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.13997
Subject(s) - ustekinumab , psoriasis , medicine , dermatologic agents , dermatology , plaque psoriasis , oncology , disease , infliximab , microbiology and biotechnology , biology , antibiotics
Currently available biologics for psoriasis target the function of TNF-α, IL-17A or IL-12/23 and include etanercept (anti-TNF receptor fusion protein), adalimumab and infliximab (anti-TNFα antibodies), anti-IL-17(receptor) molecules and ustekinumab. Ustekinumab is a fully human immunoglobulin monoclonal antibody targeting the p40 subunit shared by IL-12 and IL-23. This prevents binding to the IL-12Rβ1 receptor unit on immune cells and subsequent signaling. The Psoriasis Area and Severity Index (PASI) is used for evaluation of the efficacy of therapies in psoriasis. This article is protected by copyright. All rights reserve